Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 5/2014

01-05-2014 | Obesity (J McCaffery, Section Editor)

FTO and Obesity: Mechanisms of Association

Authors: Xu Zhao, Ying Yang, Bao-Fa Sun, Yong-Liang Zhao, Yun-Gui Yang

Published in: Current Diabetes Reports | Issue 5/2014

Login to get access

Abstract

The Fat mass and obesity associated (FTO) gene is a newly identified genetic factor for obesity. However, the exact molecular mechanisms responsible for the effect of FTO on obesity remain largely unknown. Recent studies from genome-wide associated studies reveal that genetic variants in the FTO gene are associated not only with human adiposity and metabolic disorders, but also with cancer, a highly obesity-associated disease as well. Data from animal and cellular models further demonstrate that the perturbation of FTO enzymatic activity dysregulates genes related to energy metabolism, causing the malfunction of energy and adipose tissue homeostasis in mice. The most significant advance about FTO research is the recent discovery of FTO as the first N6-methyl-adenosine (m6A) RNA demethylase that catalyzes the m6A demethylation in α-ketoglutarate - and Fe2+-dependent manners. This finding provides the strong evidence that the dynamic and reversible chemical m6A modification on RNA may act as a novel epitranscriptomic marker. Furthermore, the FTO protein was observed to be partially localized onto nuclear speckles enriching mRNA processing factors, implying a potential role of FTO in regulating RNA processing. This review summarizes the recent progress about biological functions of FTO through disease-association studies as well as the data from in vitro and in vivo models, and highlights the biochemical features of FTO that might be linked to obesity.
Literature
1.
Morabia A, Abel T. The WHO report “Preventing chronic diseases: a vital investment” and us. Soz Praventivmed. 2006;51:74.PubMedCrossRef
2.
3.•
Dai HJ, Wu JC, Tsai RT, et al. T-HOD: a literature-based candidate gene database for hypertension, obesity and diabetes. Database. 2013;2013:bas061. The authors established the T-HOD database providing the most detailed summary of obesity associated gene loci and polymorphisms uncovered to date.
4.
Rankinen T, Zuberi A, Chagnon YC, et al. The human obesity gene map: the 2005 update. Obesity. 2006;14:529–644.PubMedCrossRef
5.
Loos RJ, Bouchard C. FTO: the first gene contributing to common forms of human obesity. Obes Rev. 2008;9:246–50.PubMedCrossRef
6.
Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007;3:e115.PubMedCentralPubMedCrossRef
7.
Hinney A, Nguyen TT, Scherag A, et al. Genome wide association (GWA) study for early onset extreme obesity supports the role of fat mass and obesity associated gene (FTO) variants. PLoS One. 2007;2:e1361.PubMedCentralPubMedCrossRef
8.
Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889–94.PubMedCentralPubMedCrossRef
9.
Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39:724–6.PubMedCrossRef
10.
11.
Wojciechowski P, Lipowska A, Rys P, et al. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia. 2012;55:2636–45.PubMedCentralPubMedCrossRef
12.
Speakman JR, Rance KA, Johnstone AM. Polymorphisms of the FTO gene are associated with variation in energy intake, but not energy expenditure. Obesity. 2008;16:1961–5.PubMedCrossRef
13.
Speakman JR. FTO effect on energy demand vs food intake. Nature. 2010;464:E1; discussion E2.
14.
Wardle J, Llewellyn C, Sanderson S, et al. The FTO gene and measured food intake in children. Int J Obes. 2009;33:42–5.CrossRef
15.
Cecil JE, Tavendale R, Watt P, et al. An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med. 2008;359:2558–66.PubMedCrossRef
16.
de Luis DA, Aller R, Conde R, et al. The rs9939609 gene variant in FTO modified the metabolic response of weight loss after a 3-month intervention with a hypocaloric diet. J Investig Med. 2013;61:22–6.PubMed
17.
Haupt A, Thamer C, Staiger H, et al. Variation in the FTO gene influences food intake but not energy expenditure. Exp Clin Endocrinol Diabetes. 2009;117:194–7.PubMedCrossRef
18.
Li H, Wu Y, Loos RJ, et al. Variants in the fat mass- and obesity-associated (FTO) gene are not associated with obesity in a Chinese Han population. Diabetes. 2008;57:264–8.PubMedCrossRef
19.
Chang YC, Liu PH, Lee WJ, et al. Common variation in the fat mass and obesity-associated (FTO) gene confers risk of obesity and modulates BMI in the Chinese population. Diabetes. 2008;57:2245–52.PubMedCentralPubMedCrossRef
20.
Cheung CY, Tso AW, Cheung BM, et al. Obesity susceptibility genetic variants identified from recent genome-wide association studies: implications in a Chinese population. J Clin Endocrinol Metab. 2010;95:1395–403.PubMedCrossRef
21.
Tews D, Fischer-Posovszky P, Wabitsch M. Regulation of FTO and FTM expression during human pre-adipocyte differentiation. Horm Metab Res. 2011;43:17–21.PubMedCrossRef
22.
Wahlen K, Sjolin E, Hoffstedt J. The common rs9939609 gene variant of the fat mass- and obesity-associated gene FTO is related to fat cell lipolysis. J Lipid Res. 2008;49:607–11.PubMedCrossRef
23.
Lappalainen T, Kolehmainen M, Schwab U, et al. Gene expression of FTO in human subcutaneous adipose tissue, peripheral blood mononuclear cells and adipocyte cell line. J Nutrigenet Nutrigenomics. 2010;3:37–45.PubMedCrossRef
24.
Grunnet LG, Nilsson E, Ling C, et al. Regulation and function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose tissue. Diabetes. 2009;58:2402–8.PubMedCentralPubMedCrossRef
25.
Kloting N, Schleinitz D, Ruschke K, et al. Inverse relationship between obesity and FTO gene expression in visceral adipose tissue in humans. Diabetologia. 2008;51:641–7.PubMedCrossRef
26.
Labayen I, Ruiz JR, Ortega FB, et al. Association between the FTO rs9939609 polymorphism and leptin in European adolescents: a possible link with energy balance control. The HELENA study. Int J Obes. 2011;35:66–71.CrossRef
27.
Timpson NJ, Emmett PM, Frayling TM, et al. The fat mass- and obesity-associated locus and dietary intake in children. Am J Clin Nutr. 2008;88:971–8.PubMed
28.
Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316:1336–41.PubMedCentralPubMedCrossRef
29.
Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341–5.PubMedCentralPubMedCrossRef
30.
Samaras K, Botelho NK, Chisholm DJ, et al. Subcutaneous and visceral adipose tissue FTO gene expression and adiposity, insulin action, glucose metabolism, and inflammatory adipokines in type 2 diabetes mellitus and in health. Obes Surg. 2010;20:108–13.PubMedCrossRef
31.
32.
Li X, Liang L, Zhang M, et al. Obesity-related genetic variants, human pigmentation, and risk of melanoma. Hum Genet. 2013.
33.
Iles MM, Law MH, Stacey SN, et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet. 2013;45:428–32, 432e1.
34.
35.
Lurie G, Gaudet MM, Spurdle AB, et al. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One. 2011;6:e16756.PubMedCentralPubMedCrossRef
36.
Delahanty RJ, Beeghly-Fadiel A, Xiang YB, et al. Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol. 2011;174:1115–26.PubMedCentralPubMedCrossRef
37.
Tang H, Dong X, Hassan M, et al. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779–92.PubMedCentralPubMedCrossRef
38.
Pierce BL, Austin MA, Ahsan H. Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data. Cancer Causes Control. 2011;22:877–83.PubMedCrossRef
39.
Meyer TE, Boerwinkle E, Morrison AC, et al. Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev. 2010;19:558–65.PubMedCentralPubMedCrossRef
40.
Lewis SJ, Murad A, Chen L, et al. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One. 2010;5:e13485.PubMedCentralPubMedCrossRef
41.
Tarabra E, Actis GC, Fadda M, et al. The obesity gene and colorectal cancer risk: a population study in Northern Italy. Eur J Intern Med. 2012;23:65–9.PubMedCrossRef
42.
Nock NL, Plummer SJ, Thompson CL, et al. FTO polymorphisms are associated with adult body mass index (BMI) and colorectal adenomas in African-Americans. Carcinogenesis. 2011;32:748–56.PubMedCentralPubMedCrossRef
43.
44.
Li GQ, Chen QW, Wang L, et al. Association between FTO gene polymorphism and cancer risk: evidence from 16,277 cases and 31,153 controls. Tumor Biol. 2012;33:1237–43.CrossRef
45.
Ho AJ, Stein JL, Hua X, et al. A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A. 2010;107:8404–9.PubMedCentralPubMedCrossRef
46.
Keller L, Xu W, Wang HX, et al. The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer’s disease risk: a prospective cohort study. J Alzheimers Dis. 2011;23:461–9.PubMed
47.
Fischer J, Koch L, Emmerling C, et al. Inactivation of the FTO gene protects from obesity. Nature. 2009;458:894–8.PubMedCrossRef
48.
Tews D, Fischer-Posovszky P, Fromme T, et al. FTO deficiency induces UCP-1 expression and mitochondrial uncoupling in adipocytes. Endocrinology. 2013.
49.
Gao X, Shin YH, Li M, et al. The fat mass and obesity associated gene FTO functions in the brain to regulate postnatal growth in mice. PLoS One. 2010;5:e14005.PubMedCentralPubMedCrossRef
50.
Church C, Lee S, Bagg EA, et al. A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS Genet. 2009;5:e1000599.PubMedCentralPubMedCrossRef
51.
52.
McMurray F, Church CD, Larder R, et al. Adult onset global loss of the FTO gene alters body composition and metabolism in the mouse. PLoS Genet. 2013;9:e1003166.PubMedCentralPubMedCrossRef
53.••
Hess ME, Hess S, Meyer KD, et al. The fat mass and obesity associated gene (FTO) regulates activity of the dopaminergic midbrain circuitry. Nat Neurosci. 2013;16:1042–8. These authors reported, for the first time, that FTO regulates the demethylation of specific mRNAs in vivo and dopaminergic transmission activity. PubMedCrossRef
54.
55.
Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357:354–7.
56.
Wu Q, Saunders RA, Szkudlarek-Mikho M, et al. The obesity-associated FTO gene is a transcriptional co-activator. Biochem Biophys Res Commun. 2010;401:390–5.PubMedCentralPubMedCrossRef
57.
Kirkpatrick CL, Marchetti P, Purrello F, et al. Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One. 2010;5:e11053.PubMedCentralPubMedCrossRef
58.
Poritsanos NJ, Lew PS, Mizuno TM. Relationship between blood glucose levels and hepatic FTO mRNA expression in mice. Biochem Biophys Res Commun. 2010;400:713–7.PubMedCrossRef
59.
60.
Tung YC, Ayuso E, Shan X, et al. Hypothalamic-specific manipulation of FTO, the ortholog of the human obesity gene FTO, affects food intake in rats. PLoS One. 2010;5:e8771.PubMedCentralPubMedCrossRef
61.
McTaggart JS, Lee S, Iberl M, et al. FTO is expressed in neurons throughout the brain and its expression is unaltered by fasting. PLoS One. 2011;6:e27968.PubMedCentralPubMedCrossRef
62.
Cheung MK, Gulati P, O’Rahilly S, et al. FTO expression is regulated by availability of essential amino acids. Int J Obes. 2013;37:744–7.CrossRef
63.
Gulati P, Cheung MK, Antrobus R, et al. Role for the obesity-related FTO gene in the cellular sensing of amino acids. Proc Natl Acad Sci U S A. 2013;110:2557–62.PubMedCentralPubMedCrossRef
64.
Wang P, Yang FJ, Du H, et al. Involvement of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in brain fat mass- and obesity-associated (FTO) downregulation during energy restriction. Mol Med. 2011;17:523–32.PubMedCentralPubMed
65.
Rask-Andersen M, Almen MS, Olausen HR, et al. Functional coupling analysis suggests link between the obesity gene FTO and the BDNF-NTRK2 signaling pathway. BMC Neurosci. 2011;12:117.PubMedCentralPubMedCrossRef
66.
67.••
Jia GF, Fu Y, Zhao X, et al. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nature Chem Biol. 2011;7:885–7. This finding unveiled the physiological RNA modification substrate, m6A, of FTO in vivo and in vitro for the first time. CrossRef
68.
Gerken T, Girard CA, Tung YC, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318:1469–72.PubMedCentralPubMedCrossRef
69.
Jia G, Yang CG, Yang S, et al. Oxidative demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA by mouse and human FTO. FEBS Lett. 2008;582:3313–9.PubMedCentralPubMedCrossRef
70.
Han Z, Niu T, Chang J, et al. Crystal structure of the FTO protein reveals basis for its substrate specificity. Nature. 2010;464:1205–9.PubMedCrossRef
71.••
Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012;149:1635–46. It is one of the 2 papers describing the genome-wide distribution of m6A sites in mRNAs. It further shows that m6A sites are enriched near stop codons and in 3’ UTRs. PubMedCentralPubMedCrossRef
72.
73.
Zheng G, Dahl JA, Niu Y, et al. Sprouts of RNA epigenetics: the discovery of mammalian RNA demethylases. RNA Biol. 2013;10.
74.
75.
Niu Y, Zhao X, Wu YS, et al. N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function. Genomics Proteomics Bioinformatics. 2013;11:8–17.PubMedCrossRef
76.
77.
78.••
Fu Y, Jia GF, Pang XQ, et al. FTO-mediated formation of N6-hydroxymethyladenosine and N6-formyladenosine in mammalian RNA. Nat Commun. 2013;4:1798. The authors uncovered new intermediate modifications in the demethylation process from m6A to A by FTO. PubMedCentralPubMedCrossRef
79.
Wei CM, Gershowitz A, Moss B. Methylated nucleotides block 5′ terminus of HeLa cell messenger RNA. Cell. 1975;4:379–86.PubMedCrossRef
80.
Perry RP, Kelley DE, Friderici K, et al. The methylated constituents of L cell messenger RNA: evidence for an unusual cluster at the 5′ terminus. Cell. 1975;4:387–94.PubMedCrossRef
81.
Desrosiers RC, Friderici KH, Rottman FM. Characterization of Novikoff hepatoma mRNA methylation and heterogeneity in the methylated 5′ terminus. Biochemistry. 1975;14:4367–74.PubMedCrossRef
82.••
Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6. This is the first report on the landscape of m6A in mRNAs through an antibody-based genome-wide sequencing method. PubMedCrossRef
83.
Gulati P, Yeo GS. The biology of FTO: from nucleic acid demethylase to amino acid sensor. Diabetologia. 2013.
84.
Bokar JA, Shambaugh ME, Polayes D, et al. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3:1233–47.PubMedCentralPubMed
85.
Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18–29.PubMedCentralPubMed
86.
Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N-adenosine methylation. Nat Chem Biol. 2013;10:93–5.
87.
Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177–89.
88.
Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–63.PubMedCrossRef
89.
Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–68.PubMedCrossRef
90.
Baltz AG, Munschauer M, Schwanhausser B, et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol Cell. 2012;46:674–90.PubMedCrossRef
91.
Vilfan ID, Tsai YC, Clark TA, et al. Analysis of RNA base modification and structural rearrangement by single-molecule real-time detection of reverse transcription. J Nanobiotechnology. 2013;11:8.PubMedCentralPubMedCrossRef
92.
93.
Song CX, Clark TA, Lu XY, et al. Sensitive and specific single-molecule sequencing of 5-hydroxymethylcytosine. Nat Methods. 2012;9:75–7.CrossRef
94.
Chen B, Ye F, Yu L, et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J Am Chem Soc. 2012;134:17963–71.PubMedCrossRef
Metadata
Title
FTO and Obesity: Mechanisms of Association
Authors
Xu Zhao
Ying Yang
Bao-Fa Sun
Yong-Liang Zhao
Yun-Gui Yang
Publication date
01-05-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 5/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0486-0

Other articles of this Issue 5/2014

Current Diabetes Reports 5/2014 Go to the issue

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes

Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)

Diabetes and Hemochromatosis

Obesity (J McCaffery, Section Editor)

Review of Innovations in Digital Health Technology to Promote Weight Control

Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)

Diabetes Mellitus and Dementia

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

The Sum of Many Parts: Potential Mechanisms for Improvement in Glucose Homeostasis After Bariatric Surgery
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits